Company intelligence / Profile preview

Cardiogenesis

Irvine, California, United States

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Cardiogenesis's core product, an FDA-cleared Ho:YAG laser system for transmyocardial revascularization (TMR), has demonstrated benefits in relieving angina, increasing event-free survival, and improving exercise tolerance in patients not candidates for other reperfusion therapies. The company advanced to include combination strategies pairing TMR with stem cell delivery via its PHOENIX system, showing feasibility and CE mark approval in Europe[2][5][6]. Clinical results include established registry data and peer-reviewed studies showing effective angina relief and improved cardiac outcomes as summarized in registry and clinical trial publications[6][8].

Therapeutic areas: Cardiovascular
Modalities: DeviceCell therapy
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on Cardiogenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cardiogenesis.

Explore the full profile